<sup>99</sup>Tc<sup>m</sup>-MIBI用于乳腺癌诊断的评价

何建华

⁹⁹Tc^m-MIBI用于乳腺癌诊断的评价

何建华

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 2: (64-67)

引用本文:

Citation:

⁹⁹Tc^m-MIBI用于乳腺癌诊断的评价

何建华

402160 重庆, 重庆市第二人民医院核医学科

作者简介: 何建华(1963年-),男,重庆市人,主任,主要从事临床核医学珍断和治疗研究。;

中图分类号: R737.9;R817.4

Evaluation of ⁹⁹Tc^m-MIBI scintigraphy in the diagnosis of breast cancer

HE Jian-hua

Department of Nuclear Medicine, Second People's Hospital of Chongqing City, Chongqing 400026, China
CLC number: R737.9;R817.4

摘要: ⁹⁹Tc^m-MIBI(⁹Tc^m-甲氧基异丁基异腈)用于乳腺癌原发病灶诊断具有较高的灵敏度、特异性和准确率,与其他检测技术的对比研究显示其具有良好的应用前景,与其他检测技术联合应用可进一步提高诊断的准确性。
- 乳腺癌 /
- ⁹⁹Tc^m-甲氧基异丁基异腈 /
- 对比研究
Abstract: ⁹⁹Tc^m-MIBI(⁹⁹Tc^m-sestamibi)scintigaphy has high sensitivity, specificity and accuracy in diagnosis of breast can-cer. It can also be used to detect axillary lymph node metastases. Furthermore, associated with other methods, ⁹⁹Tc^m-MIBI seintigraphy improve on the accuracy of detecting breast cancer.
- breast cancer /
- ⁹⁹Tc^m-sestamibi /
- comparison study
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Mekhmandarov S,Sandbank J,Cohen M, et al. Technetium-99m-MIBI scintimammography in palpable and nonpalpable breast lesions[J].J Nucl Med,1998,39(1):86-91.
[2]	Melloul M,Paz A,Ohana G, et al. Double-phase ⁹⁹Tc-sestamibi scintimmography and trans-scan in diagnosing breast cancer[J].J Nucl Med,1999,140(3):376-380.
[3]	Becherer A,Heibich T,Staudenherz A, et al. The diagnostic value of planar and SPECT scintimammography in different age groups[J].Nucl Med Commun,1997,18:710-718.
[4]	Maublant J,de Latour M,Mestas D, et al. Technetium-99msestamibi uptake in breast tumor and associated lymph nodes[J].J Nucl Med,1996,37:922-925.
[5]	Cordobes MD,Starzec A,Delmon-Moingeon L, et al. Technetium-99m-ses tamibi uptake by human benign and malignant breast tumor cells:Correlation with mdr gene expression[J].J Nucl Med,1996,37:286-289.
[6]	Yoon JH,Bom HS,Song HC, et al. Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and Pglycoprotein expression in patients with untreated breast cancer[J].Clin Nucl Med,1999,24(5):314-318.
[7]	Kao CH,Tsai SC,Liu TG, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium 99m MIBI scintimammography findings[J].Cancer Res,2001,15(61):1412-1414.
[8]	Mansi L,Rambaldi PF,Procaccini E, et al. Scintimammography with ⁹⁹Tc^m-tetrofosmin in the diagnosis of breast cancer and lymph node metastases[J].Eur J Nucl Med,1996,23:932-939.
[9]	Akcay MN,Akin Y,Karabag B, et al. ⁹Tc^m-tetrofosmin in breast carcinoma and axillary lymph node metastases:a comparative study with ⁹⁹Tc^m-MIBI[J].Clin Nucl Med,1997,22:832-834.
[10]	Rodrigues M,Chehne F,Kalinowska W, et al. Uptake of ⁹Tc^m-MIBI and ⁹⁹Tc^m-tetrofosmin into malignant versus nonmalignant breast cell lines[J].J Nucl Med,2000,41:1495-1499.
[11]	AMANO S,Inoue T,Tomiyoshi K, et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer[J].J Nucl Med,1998.1424-1427.
[12]	Palmedo H,Bender H,Grüwald F, et al. Comparison of ¹⁸F-FDG PET and ⁹⁹Tc^m-MIBI scintimammography in the detection of breast tumours[J].Eur J Nucl Med,1997,24:1138-1145.
[13]	Inbriaco M,Vecchio SD,Riccardi A, et al. Scintimammography with ⁹⁹Tc^m-MIBI versus dynamic MRI for non-invasive characterization of breast masses[J].Eur J Nucl Med,2001,28:56-63.
[14]	Taillefer R. The role of 99mTc-sestamibi and other conventional radio-pharmaceuticals in breast cancer diagnosis[J].Semin Nucl Med,1999,29:22-23.
[15]	Khalkhali I,Cutrone J,Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions:Clin and pathological follow-up[J].J Nucl Med,1995,36:1784-1789.
[16]	Buscombe JR,Cwikla JB,Holloway B, et al. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves[J].J Nucl Med,2001,42:3-8.
[17]	Buffaz PD,Gauchez AS. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?[J].Eur J Nucl Med,1999,26:8-11.

[1]	章斌 . ⁹⁹Tc^m-tetrofosmin在乳腺癌及其转移灶显像中的应用. 国际放射医学核医学杂志, 2001, 25(1): 12-15.
[2]	贾志云 , 邓候富 . ⁹⁹Tc^m-甲氧基异丁基异腈显像在白血病中的应用价值. 国际放射医学核医学杂志, 2005, 29(6): 252-254.
[3]	川玲 , 赵文锐 . ⁹⁹Tc^m-MIBI在检测乳腺癌中的作用. 国际放射医学核医学杂志, 2000, 24(4): 155-157.
[4]	程兵 . ⁹⁹Tc^m-MIBI显像检测乳腺癌多药耐药. 国际放射医学核医学杂志, 2002, 26(2): 67-71.
[5]	张一秋 , 石洪成 . ⁹⁹Tc^m-甲氧基异丁基异腈SPECT预测肺癌多药耐药及化疗疗效. 国际放射医学核医学杂志, 2008, 32(6): 329-332.
[6]	陆汉魁 , 林祥通 , 刘家慧 , 林汉 . 乳腺癌和前列腺癌的类固醇受体显像研究现状. 国际放射医学核医学杂志, 1996, 20(3): 106-109.
[7]	陈璟 , 吴华 . 乳腺癌前哨淋巴结探查的研究进展. 国际放射医学核医学杂志, 2002, 26(5): 222-224.
[8]	黄建敏 , 曲雁 , 潘莉萍 . 恶性骨肿瘤多药耐药的⁹⁹Tc^m-MIBI体层显像研究. 国际放射医学核医学杂志, 2005, 29(4): 169-170.
[9]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[10]	余丰文 , 冯彦林 , 贺小红 , 刘德军 , 温广华 , 袁建伟 . PET-CT与钼靶X线、B超定性诊断乳腺癌的临床对比研究. 国际放射医学核医学杂志, 2006, 30(3): 148-151.